on June 14, 2007
Published online before print June 14, 2007, doi: 10.1161/ATVBAHA.107.145151
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 2, 2007
Accepted on May 22, 2007
A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia
H. J. Avis ;
From the Departments of Vascular Medicine (H.J.A., M.N.V., M.D.T., J.J.P.K.), Pediatrics (F.A.W.), and Clinical Epidemiology, Biostatistics, and Bioinformatics (B.A.H.), Academic Medical Centre, Amsterdam, The Netherlands; and the Metabolic and Atherosclerosis Research Centre (E.A.S.), Cincinnati, Ohio.
* To whom correspondence should be addressed. E-mail: b.a.hutten{at}amc.uva.nl.
Objective--Functional and morphological changes of the arterial wall already present in young children with heterozygous familial hypercholesterolemia (HeFH) suggest that treatment should be initiated early in life to prevent premature atherosclerotic cardiovascular disease. The purpose of this study was to assess the efficacy and particularly safety of statin therapy in children with HeFH.
Methods and Results--We performed a meta-analysis of randomized, double-blind, placebo-controlled trials evaluating statin therapy in children aged 8 to 18 years with HeFH. Six studies (n=798 children) with 12 to 104 weeks of treatment were included. Total cholesterol, LDL cholesterol, and apolipoprotein B were significantly reduced, whereas HDL cholesterol and apolipoprotein A1 were significantly increased by statin therapy. No statistically significant differences were found between statin- and placebo-treated children with respect to the occurrence of adverse events (RR 0.99; 95% CI: 0.79 to 1.25), sexual development (RR of advancing 
1 stage Tanner classification 0.96; 95% CI: 0.79 to 1.17), muscle toxicity (RR of CK 10 times the upper limit of normal [ULN] 1.38; 95% CI: 0.18 to 10.82), or liver toxicity (RR of 3 times the ULN for ASAT 0.98; 95% CI: 0.23 to 4.26 and for ALAT 2.03; 95% CI: 0.24 to 16.95). We found a minimal difference in growth in favor of the statin group (0.33 cm; 95% CI: 0.03 cm to 0.63 cm).
Conclusion--In addition to the fact that statin treatment is efficacious, our results support the notion that statin treatment in children with HeFH is safe. Thus, even though further studies are required to assess lifelong safety, statin treatment should be considered for all children aged 8 to 18 with HeFH.
Key words: familial hypercholesterolemia • children • statins • safety • meta-analysis
This article has been cited by other articles:
 |
|
 |
|
  P. O. Kwiterovich Jr. Recognition and Management of Dyslipidemia in Children and Adolescents J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4200 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. van der Graaf, C. Cuffie-Jackson, M. N. Vissers, M. D. Trip, C. Gagne, G. Shi, E. Veltri, H. J. Avis, and J. J.P. Kastelein Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia J. Am. Coll. Cardiol., October 21, 2008; 52(17): 1421 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nagasaka, T. Miida, K. Hirano, A. Ota, T. Yorifuji, T. Takatani, H. Tsukahara, M. Takayanagi, S.-P. Hui, K. Kobayashi, et al. Reduced Apolipoprotein E-Rich High-Density Lipoprotein Level at Birth Is Restored to the Normal Range in Patients with Familial Hypercholesterolemia in the First Year of Life J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 779 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tabas, K. J. Williams, and J. Boren Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications Circulation, October 16, 2007; 116(16): 1832 - 1844. [Abstract] [Full Text] [PDF]
|
|